Thermo Fisher Scientific (NYSE: TMO) Reports Strong Q2 2026 Results and Raised Outlook

• Strong Financial Performance: Thermo Fisher Scientific (NYSE: TMO) reported a 10% increase in Q2 2026 revenue to $11.99 billion and a 13% rise in adjusted EPS to $6.03, exceeding analyst expectations.
• Improved Profitability & Segment Growth: The company's adjusted operating margin expanded to 22.8%, driven by strong performance in the Life Sciences Solutions segment, which saw revenue grow 12.6% to $2.82 billion.
• Raised Full-Year Outlook: Following these robust results, Thermo Fisher Scientific increased its financial outlook for the full year, citing improved customer activity and contributions from recent acquisitions.

Thermo Fisher Scientific (NYSE: TMO) is a global leader in the scientific field. The company provides analytical instruments, laboratory equipment, and software for research, analysis, and diagnostics. With a large market capitalization of approximately $212.69 billion, it is a major player in the life sciences and healthcare industries.

On July 24, 2026, RBC Capital maintained its Sector Perform rating for Thermo Fisher Scientific, which suggests the stock should perform in line with its industry. The firm raised its price target to $580 from $490. This update came when the stock's price was $572.32, as published by TheFly.

The new price target is supported by strong financial results. As reported by BusinessWire, the company’s second-quarter revenue for 2026 increased by 10% to $11.99 billion. Adjusted earnings per share (EPS), a measure of profitability from core operations, grew 13% to $6.03. This figure surpassed analyst expectations by 5.67%, as detailed by Zacks Investment Research.

Profitability also showed significant improvement. The company's adjusted operating margin, which indicates how much profit it makes from its main business activities, expanded to 22.8%. As highlighted by Zacks Investment Research, the Life Sciences Solutions segment was a strong performer, with its revenue growing 12.6% to $2.82 billion.

Due to these results, Thermo Fisher raised its financial outlook for the full year. According to MarketBeat, this is a result of improving customer activity and contributions from recent acquisitions.